	se type a plus sign (+) inside this box er the Paperwork Reduction Act of 1995, no persons are required to respond to	U.S. Patent and Trader	proved for use through 10/31/20 mark Office: U.S. DEPARTME	ENT OF COMM	-00311	
44	Substitute for form 1449A1PT0		Complete if Known	OHC	 	E T
No.	/ INFORMATION DISCLOSURE	Application Number	10/016,969	- E	7	
	STATEMENT BY APPLICANT	Filing Date	Dec 14, 2001	<u> </u>	0	П
(year	(use as many sheets as necessary)	First Named Inventor	Pittner, R.A.		9 2	
	(use as many sneeds as necessary)	Group Art Unit	1646		00;	$\overline{\mathbf{H}}$
		Examiner Name	Ruixiang, Li	22	10	

Attorney Docket Number

24001-010 US

			U.S. PATEN	Γ DOCUMENTS		
		U.S. Patent Document	Publication Date	Name of Patentee or Applicant	Pages, Columns, Lines, Where Relevan	
Examiner Initials *	Cite No ¹	Number Kind Code ² (if known)	MM-DD-YYYY	of Cited Document	Passages or Relevant Figures Appear	
RLi		US 4,839,343	06-13-1989	Waeber, et al.		

Sheet

		FOREIG	N PATENT DOC	CUMENTS	_	
		Foreign Patent Document		Name of Patentee or Applicant	Pages, Columns, Lines,	
Examiner Initials*	Cite No ¹	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	of Cited Document	Where Relevant Passages or Relevant Figures Appear	
						T ⁶
RLi		EP 0 992 239 A	04-12-2000	Banyu Pharma Co Ltd		
		WO 99 15516	04-01-1999	Banyu Pharm Co Ltd	English Abstract Only	
		WO 00 68197	11-16-2000	Ortho McNeil Pharm	-	
		WO 01 62737	08-30-2001	Ortho McNeil Pharm		
$\overline{}$		WO 01 76631	10-18-2001	Cedars Sinai Medical		

Examiner Signature Ruskian	9 L	Date Considered	16/12/2002

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number(optional). ² See attached Kinds of U.S. Patent Documents, at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box Under the Paperwork Reduction Act of 1995, no persons are required to respond			PTO/SB/08A (08-00 Approved for use through 10/31/2002. 0MB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it contains a valid 0MB control number.			
2002 N Subst	itute for form 1449A1PT0			Complete if Known	HCH HCH	그
A CENT	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/016,969	<u>ස</u> දි	וונ
MAKA SI			Filing Date	Dec 14, 2001	- Z	₹](
			First Named Inventor	Pittner, R.A.	THI C	ַ װַ
(use as many sheets as necessary)		Group Art Unit	1646	16	ے ا	
			Examiner Name	Ruixiang, Li	9,	ឡី π
Sheet	of		Attorney Docket Number	24001-010 US	29	_ ار
					8	_

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	1
Examiner Initials *	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
RLi	1	HAGAN, M.M. et al. "Effect of Naloxone and Antidepressants on Hyperphagia Produced by Peptide YY" Pharmacology Biochemistry and Behavior, 45(4): 941-944 (1993)	
		WIDDOWSON P.S. et al. "Distribution of (Leu31, Pro34)NPY-sensitive, BIBP3226-insensitive (1251)PYY(3-36) binding sites in rat brain: Possible relationship to Y5 NPY receptors", Brain Research 778(1): 242-250 (1997)	
1		DERWENT SEARCH: Class B02, AN 1999-254678 XP002201834	

Examiner Signature	Ruisiang L.	Date Considered	11/12/2002

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.